CR20150523A - Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas - Google Patents

Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas

Info

Publication number
CR20150523A
CR20150523A CR20150523A CR20150523A CR20150523A CR 20150523 A CR20150523 A CR 20150523A CR 20150523 A CR20150523 A CR 20150523A CR 20150523 A CR20150523 A CR 20150523A CR 20150523 A CR20150523 A CR 20150523A
Authority
CR
Costa Rica
Prior art keywords
dihydroimidazo
kinazolins
substituted
compound
quinazolines
Prior art date
Application number
CR20150523A
Other languages
English (en)
Inventor
Ningshu Liu
Katja Haike
Juliane Paul
Antje Margret Wengner
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CR20150523A publication Critical patent/CR20150523A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

El uso de un compuesto del tipo de las 2,3-dihidroimidazo[1,2-c] quinazolinas, o de una composición farmacéutica que lo contiene, como único agente activo, o de una combinación del compuesto que se ha descripto o una composición farmacéutica que lo contiene y uno o más agentes activos adicionales en la elaboración de un medicamento útil para tratar o prevenir unlinfoma no Hodgkin (NHL).
CR20150523A 2013-04-08 2015-10-08 Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas CR20150523A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13162710 2013-04-08
EP13184240 2013-09-13
PCT/EP2014/056768 WO2014166820A1 (en) 2013-04-08 2014-04-04 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Publications (1)

Publication Number Publication Date
CR20150523A true CR20150523A (es) 2016-01-29

Family

ID=50439383

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150523A CR20150523A (es) 2013-04-08 2015-10-08 Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas

Country Status (28)

Country Link
US (2) US9999623B2 (es)
EP (1) EP2983669B1 (es)
JP (1) JP6368353B2 (es)
KR (1) KR102304108B1 (es)
CN (1) CN105263497B (es)
AP (1) AP2015008750A0 (es)
AU (1) AU2014253348B2 (es)
BR (1) BR112015025304B1 (es)
CA (1) CA2908776C (es)
CL (1) CL2015002978A1 (es)
CR (1) CR20150523A (es)
CU (1) CU24400B1 (es)
DO (1) DOP2015000256A (es)
EA (2) EA031493B9 (es)
ES (1) ES2708350T3 (es)
HK (1) HK1220121A1 (es)
IL (1) IL241543B (es)
JO (1) JOP20140141B1 (es)
MX (1) MX2015014171A (es)
MY (1) MY192626A (es)
NI (1) NI201500148A (es)
PE (1) PE20151780A1 (es)
PH (1) PH12015502317A1 (es)
SG (2) SG10201710539QA (es)
TN (1) TN2015000452A1 (es)
TW (2) TWI689307B (es)
UA (2) UA122822C2 (es)
WO (1) WO2014166820A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP3077003A1 (en) 2013-12-03 2016-10-12 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016087488A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives
WO2016087490A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CN107864625B (zh) 2015-03-09 2021-05-28 拜耳制药股份公司 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN113480542A (zh) 2015-07-02 2021-10-08 安塞塔制药公司 化合物的固体形式和制剂
AU2017214230A1 (en) * 2016-02-01 2018-08-09 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
CN109072307A (zh) * 2016-02-01 2018-12-21 拜耳制药股份公司 Copanlisib生物标志物
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2017221092A1 (en) * 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
JP2019524872A (ja) * 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
US10925880B2 (en) 2016-09-23 2021-02-23 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
BR112019023632A2 (pt) 2017-05-18 2020-08-18 Jiangsu Hengrui Medicine Co., Ltd. uso do inibidor de ezh2 combinado com o inibidor de btk na preparação de fármacos para tratamento de tumor
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
BR112020005105A2 (pt) 2017-09-13 2020-09-15 Guangdong Oppo Mobile Telecommunications Corp., Ltd. método de processamento de dados e dispositivo terminal
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CN115315424A (zh) * 2019-10-15 2022-11-08 拜耳公司 2-甲基-氮杂-喹唑啉
JP7440360B2 (ja) 2020-06-30 2024-02-28 東日本旅客鉄道株式会社 山形鋼材の研磨装置
WO2022199373A1 (zh) * 2021-03-26 2022-09-29 上海璎黎药业有限公司 一种喹唑啉化合物及药物组合物的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1400959A (en) 1919-04-26 1921-12-20 Ste Chim Usines Rhone Process and apparatus for carrying out chemical reactions by catalysis
US1364099A (en) 1919-09-10 1921-01-04 Flannery Bolt Co Staybolt structure for boilers
US1400975A (en) 1920-10-11 1921-12-20 Page Henry Benjiman Dirigible headlight for motor-vehicles
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JP2003277383A (ja) * 2002-03-14 2003-10-02 Bayer Ag 光学活性ピリジン誘導体およびそれを含む医薬
US7511041B2 (en) 2002-09-30 2009-03-31 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2244721A4 (en) 2008-01-14 2017-01-18 Bayer Intellectual Property GmbH Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2558126A2 (en) 2010-04-16 2013-02-20 Bayer Intellectual Property GmbH Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
AU2011251032B2 (en) 2010-05-14 2015-07-23 Lg Electronics Inc. Method for allocating resources in a wireless communication system and a device for the same
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JP5790016B2 (ja) 2011-02-18 2015-10-07 コベルコ建機株式会社 ハイブリッド建設機械
US9133162B2 (en) * 2011-02-28 2015-09-15 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
WO2012121953A1 (en) 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Methods and pharmaceutical compositions for treating lymphoid malignancy
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP2726634B1 (en) * 2011-07-01 2017-02-22 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
WO2013169858A1 (en) * 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US8993891B2 (en) 2012-06-28 2015-03-31 Thomas & Betts International, Inc. Lift and pivot grommet
CA2932221C (en) 2013-12-03 2022-02-22 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN107864625B (zh) 2015-03-09 2021-05-28 拜耳制药股份公司 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
SG11201707239WA (en) 2015-03-09 2017-10-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Also Published As

Publication number Publication date
SG10201710539QA (en) 2018-01-30
CA2908776C (en) 2021-08-10
KR20150138858A (ko) 2015-12-10
CL2015002978A1 (es) 2016-04-15
US20160058770A1 (en) 2016-03-03
EA201792650A1 (ru) 2018-04-30
DOP2015000256A (es) 2015-12-31
TWI675663B (zh) 2019-11-01
EP2983669B1 (en) 2018-10-24
US20180193349A1 (en) 2018-07-12
WO2014166820A1 (en) 2014-10-16
MX2015014171A (es) 2015-12-16
IL241543B (en) 2019-08-29
BR112015025304B1 (pt) 2022-09-27
AP2015008750A0 (en) 2015-09-30
CN105263497B (zh) 2019-04-30
US9999623B2 (en) 2018-06-19
PE20151780A1 (es) 2015-12-20
JP6368353B2 (ja) 2018-08-01
TN2015000452A1 (en) 2017-04-06
NZ712033A (en) 2021-03-26
EP2983669A1 (en) 2016-02-17
MY192626A (en) 2022-08-29
US10226469B2 (en) 2019-03-12
UA122822C2 (uk) 2021-01-06
JP2016515601A (ja) 2016-05-30
EA037577B1 (ru) 2021-04-16
NI201500148A (es) 2015-11-30
HK1220121A1 (zh) 2017-04-28
CU24400B1 (es) 2019-04-04
EA031493B9 (ru) 2019-12-18
UA119537C2 (uk) 2019-07-10
CA2908776A1 (en) 2014-10-16
ES2708350T3 (es) 2019-04-09
TW201517909A (zh) 2015-05-16
EA201591932A1 (ru) 2016-04-29
AU2014253348B2 (en) 2019-05-23
EA031493B1 (ru) 2019-01-31
AU2014253348A1 (en) 2015-10-08
JOP20140141B1 (ar) 2021-08-17
TWI689307B (zh) 2020-04-01
CN105263497A (zh) 2016-01-20
TW201924690A (zh) 2019-07-01
SG11201507265XA (en) 2015-10-29
PH12015502317A1 (en) 2016-02-10
CU20150140A7 (es) 2016-10-28
KR102304108B1 (ko) 2021-09-23
BR112015025304A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
CO2017001994A2 (es) Compuestos activos hacia bromodominios
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
GT201400043A (es) Imidazopiridazinas sustituidas con amino
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
NI201500118A (es) Imidazopiridazinas sustituidas
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
CU20130134A7 (es) Uso de 2,3- dihidroimidazo [1,2 - c] quinazolinas sustituidas
CL2015002060A1 (es) Compuestos.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.